ArticleScience translational medicine2022
Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.
Open access · greenAbstract read
In one paragraph
Article in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 30 citations in OpenAlex.
- Haematopoietic Cells Deficient for Calreticulin or Expressing Its Oncogenic Variants Maintain Functional Antigen Presentation.Journal of cellular and molecular medicine · 2026Article
- Review
- From Universal Aspiration to Precision Immunization: A Hypothesis Framework for Antigen-Defined, HLA-Restricted Cancer Vaccines.Vaccines · 2026Review
- Article
- Sequence-Anchored Shared Tumor-Specific Epitopes for Pre-Manufactured HLA-Matched mRNA Cancer Vaccine Libraries: A Pan-Cancer Framework.Biomolecules · 2026Article
- No evidence of immunosurveillance in mutation-hotspot-driven clonal hematopoiesis.Nature genetics · 2026Article
- Immunogenetic and Transcriptomic Evidence Implicating the NKG2D-MICA/MICB Axis in CALR-Mutated Myeloproliferative Neoplasms.Cancers · 2026Article
- EPIC: multi-objective guided diffusion for epitope design in TCR-pMHC complexes.Bioinformatics (Oxford, England) · 2026Article
- Mutant calreticulin-directed immunotherapies in myeloproliferative neoplasms.Blood neoplasia · 2026Review
- Mutant calreticulin-Cancer driver and Achilles' heel for ET?HemaSphere · 2026Article
- Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis.Blood · 2026Review
- A machine learning-based method to optimize the immunogenicity of human leukocyte antigen class I-restricted neoantigens.Briefings in bioinformatics · 2025Article
- Challenges in the Evolving Role of Calreticulin as a Promising Target for Precision Medicine in Myeloproliferative Neoplasms.Cancers · 2025Review
- Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives.American journal of hematology · 2025Review
- Research trends in essential thrombocythemia from 2001 to 2024: a bibliometric analysis.Discover oncology · 2025Article
- Calreticulin-From the Endoplasmic Reticulum to the Plasma Membrane-Adventures of a Wandering Protein.Cancers · 2025Review
- Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications.Current hematologic malignancy reports · 2025Review
- Differential modulation of mutant CALR and JAK2 V617F-driven oncogenesis by HLA genotype in myeloproliferative neoplasms.Frontiers in immunology · 2024Article
- Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects.Molecular cancer · 2023Review
- Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.Bone marrow transplantation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors at 9 institutions in 2 countries.
Mathieu GigouxLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-1831-7597
Morten O HolmströmDepartment of Oncology, National Center for Cancer Immune Therapy, Herlev Hospital, Herlev 2730, Denmark.ORCID 0000-0002-3764-8578
Roberta ZappasodiLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-7031-6671
Joseph J ParkLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-1311-5416
Stephane PourpeLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Cansu Cimen BozkusIcahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0001-7834-4792
Levi M B MangarinLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-1219-6998
David RedmondLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-0983-8606
Svena VermaLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Sara SchadLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Mariam M GeorgeLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-3166-6844
Divya VenkateshLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Arnab GhoshLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0003-3355-5427
David HoyosComputational Oncology, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Zaki MolviWeill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0001-6728-4835
Baransel KamazDepartment of Medicine, Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-9910-6141
Anna E MarnethDepartment of Medicine, Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-9065-0581
William DukeDepartment of Medicine, Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Matthew J LeventhalBroad Institute, Cambridge, MA 02142, USA.ORCID 0000-0002-5995-5202
Max JanDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-7071-5517
Vincent T HoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Gabriela S HobbsDepartment of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-0199-9333
Trine Alma KnudsenDepartment of Hematology, Zealand University Hospital, Roskilde 4000, Denmark.ORCID 0000-0001-9829-3099
Vibe SkovDepartment of Hematology, Zealand University Hospital, Roskilde 4000, Denmark.ORCID 0000-0003-0097-7826
Lasse KjærDepartment of Hematology, Zealand University Hospital, Roskilde 4000, Denmark.
Thomas Stauffer LarsenDepartment of Hematology, Odense University Hospital, Odense 5000, Denmark.
Dennis Lund HansenDepartment of Hematology, Odense University Hospital, Odense 5000, Denmark.ORCID 0000-0002-4478-1297
R Coleman LindsleyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-9822-806X
Hans HasselbalchDepartment of Hematology, Zealand University Hospital, Roskilde 4000, Denmark.ORCID 0000-0003-3936-8032
Jacob H GrauslundDepartment of Oncology, National Center for Cancer Immune Therapy, Herlev Hospital, Herlev 2730, Denmark.
Thomas L LisleDepartment of Oncology, National Center for Cancer Immune Therapy, Herlev Hospital, Herlev 2730, Denmark.ORCID 0000-0002-6667-7706
Özcan MetDepartment of Oncology, National Center for Cancer Immune Therapy, Herlev Hospital, Herlev 2730, Denmark.ORCID 0000-0002-3256-7592
Patrick WilkinsonJanssen Oncology Therapeutic Area, Janssen Research and Development, LLC, Pharmaceutical Companies of Johnson & Johnson, Spring House, PA 19002, USA.ORCID 0000-0002-2274-4110
Benjamin GreenbaumComputational Oncology, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Manuel A SepulvedaJanssen Oncology Therapeutic Area, Janssen Research and Development, LLC, Pharmaceutical Companies of Johnson & Johnson, Spring House, PA 19002, USA.ORCID 0000-0001-7196-7823
Timothy ChanWeill Cornell Medical College, New York, NY 10065, USA.ORCID 0000-0002-9265-0283
Raajit RampalHuman Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Mads H AndersenDepartment of Oncology, National Center for Cancer Immune Therapy, Herlev Hospital, Herlev 2730, Denmark.ORCID 0000-0002-2914-9605
Omar Abdel-WahabHuman Oncology and Pathogenesis Program and Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-3907-6171
Nina BhardwajParker Institute for Cancer Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.ORCID 0000-0003-1865-4187
Jedd D WolchokLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0001-6718-2222
Ann MullallyDepartment of Medicine, Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-9727-8495
Taha MerghoubLudwig Collaborative and Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.ORCID 0000-0002-1518-5111
Memorial Sloan Kettering Cancer Center · USHerlev Hospital · DKHarvard University · USZealand University Hospital · DKBrigham and Women's Hospital · USBroad Institute · USIcahn School of Medicine at Mount Sinai · USJohnson & Johnson (United States) · USOdense University Hospital · DK
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MIMMUNIZATION AGAINST MELANOMA DIFFERENTIATION ANTIGENSR01CA056821 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI WOLCHOK, JEDD D. · 1992 to 2020
$5.7MFunctional and Molecular Dissection of Mutant Calreticulin in Myeloproliferative NeoplasmsR01HL131835 · NHLBI · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI Ann Mullally · 2016 to 2026
$4.1MNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA056821NHLBI NIH HHS R01 HL131835
Abstract
The majority of JAK2
Indexed as
Cancer VaccinesMyeloproliferative DisordersNeoplasmsAnimalsCalreticulinHumansJanus Kinase 2Major Histocompatibility ComplexMiceMice, Inbred C57BLMutationPeptidesVaccines, SubunitCalreticulinCancer VaccinesJanus Kinase 2PeptidesVaccines, Subunit
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.